Schrodinger Inc
(STU:43Z)
€
16.325
-0.015 (-0.09%)
Market Cap: 1.19 Bil
Enterprise Value: 955.04 Mil
PE Ratio: 0
PB Ratio: 2.71
GF Score: 58/100 Schrodinger Inc at Citi BioPharma Conference Transcript
Sep 07, 2022 / 02:30PM GMT
David Neil Lebowitz
Citigroup Inc., Research Division - Research Analyst
So good morning, everyone. I'm Dave Lebowitz, one of the biotech analysts. And welcome here to the Citi's 17th Annual BioPharma Conference. This is my first. I guess, let's just kick it right off here. On stage with me, we have Schrödinger. We have CEO, Ramy Farid. And we also have Karen, you'll have to help me with your last name.
Karen Akinsanya;dinger
SchrÃ;Inc. - President of Research & Development Therapeutics
¶ -
Akinsanya.
David Neil Lebowitz;Ramy Farid;dinger
Citigroup Inc., Research Division - Research Analyst;SchrÃ;Inc. - CEO, President &
I'm the worst -- I botched more names than I've said right correctly. Anyway, if you could just start off by telling me the overall mission of Schrödinger. You're certainly a very unique company from, frankly, both sides of your businesses compared to other competitors. Tell us about Schrödinger.
- ¶
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot